SCHEMBL6997073

SCHEMBL6997073

Cn1cc2c(=O)n(Cc3cccc(Cl)c3)cnc2n1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FSCN1 Q16658 2/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
GLA P06280 1/20 0.54
HTT P42858 1/20 0.54
UBE2N P61088 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MAPK1 P28482 1/20 0.51
MMP13 P45452 1/20 0.50
BRD4 O60885 1/20 0.47
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 2/20 0.44
MAPT P10636 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44
RECQL P46063 1/20 0.44
YTHDC1 Q96MU7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7003827 0.87 SMN1; SMN2 (0.49) SMN1; SMN2L3MBTL1BRD4PDE4APDE4B
SCHEMBL7002192 0.87 HPGD (0.49) FSCN1SMN1; SMN2HTTMMP13ALDH1A1
SCHEMBL7081478 0.86 TP53 (0.52) MAPK1TP53
SCHEMBL7077867 0.81 TSHR (0.47) SMN1; SMN2HTTL3MBTL1MAPK1ALDH1A1
SCHEMBL7077434 0.81 KDM4E (0.45) L3MBTL1MAPK1MMP13ALDH1A1TP53
SCHEMBL7003576 0.81 LMNA (0.48) FSCN1SMN1; SMN2HTTMMP13TP53
SCHEMBL7083035 0.81 TSHR (0.57) SMN1; SMN2HTTMAPK1ALDH1A1TP53
SCHEMBL7000183 0.80 SMN1; SMN2 (0.51) FSCN1SMN1; SMN2HTTL3MBTL1MMP13
SCHEMBL7000340 0.78 ALDH1A1 (0.50) SMN1; SMN2HTTMAPK1BRD4ALDH1A1
SCHEMBL7002718 0.77 TRPA1 (0.48) SMN1; SMN2MMP13ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same ELBION AG (DE) 2003-10-02 US claimed
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same ELBION AG (DE) 2003-10-02 US disclosed
EP-1311510-A1 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME ARZNEIMITTELWERK DRESDEN GMBH (DE) 2003-05-21 EP disclosed
WO-2002018387-A1 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME ELBION AG (DE) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same DDO, GRIN3A, GRIK4 FSCN1 4032/4885SMN1; SMN2 861/4885GLA 3915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.